Abstracts tagged "Biologics"

Abstract Number: 140 • 2015 ACR/ARHP Annual Meeting
Identifying Psoriatic Arthritis and Ankylosing Spondylitis Patients Responsible for the Highest Costs of Care: Data from a Large US Cohort
Jacqueline B. Palmer, Yunfeng Li, Vivian Herrera and Minlei Liao, Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: The economic burden of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in the biologics era is not well understood in the US population. Using…
Abstract Number: 956 • 2015 ACR/ARHP Annual Meeting
The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events
Joost Swart¹, Angela Pistorio², Francesca Bovis³, Ekaterina Alexeeva⁴, Michael Hofer⁵, Susan Nielsen⁶, Jordi Anton⁷, Alessandro Consolaro⁸, Violeta Vladislava Panaviene⁹, Valda Stanevicha¹⁰, Maria Trachana¹¹, Constantin Ailioaie¹², Florence Uettwiller¹³, Fabrizio De Benedetti¹⁴, Elena Tsitsami¹⁵, Berit Flato¹⁶, Pavla Dolezalová¹⁷, Tamás Constantin¹⁸, Troels Herlin¹⁹, Sylvia Kamphuis²⁰, Sujata Sawhney²¹, Despoina Maritsi²², Veronika Vargova²³, Luca Villa⁸, Chiara Pallotti⁸, Angelo Ravelli³, Alberto Martini²⁴, Nico Wulffraat²⁵, Nicolino Ruperto²⁶ and on behalf of for PRINTO, ¹Pediatric Rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Servizio di Epidemiologia e Biostatistica, Istituto Giannina Gaslini, Genoa, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ⁵Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁶Pediatric Rheumatology Unit, Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark, ⁷Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ⁸Pediatria II - Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁹Centre of Pediatrics, Vilnius University, Vilnius, Lithuania, ¹⁰Department of Paediatrics, Riga Stradins University, Riga, Latvia, ¹¹1st Department of Pediatrics, Aristotle University, Thessaloniki, Greece, ¹²II Pediatric Clinic, Private Medical Clinic, IASI, Romania, ¹³Unité d'Immunologie, Hématologie et Rhumatologie Pediatrique, Université Paris-Descartes, IMAGINE Institute, Hôpital Necker-Enfants Malades, Paris, France, ¹⁴Reumatologia, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ¹⁵First Department of Pediatrics, Children Hospital Aghia Sophia, Athens, Greece, ¹⁶Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁷Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ¹⁸Unit of Paediatric Rheumatology, 2nd Dpt of Pediatrics, Semmelweis University, Budapest, Hungary, ¹⁹Department of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark, ²⁰Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²¹Paediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, ²²2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ²³1st Department of Paediatrics and Adolescent Medicine, Šafarik University and Children Faculty Hospital in Košice, Kosice, Slovakia, ²⁴Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy, ²⁵Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²⁶Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA) has greatly changed in the past 15 years thanks to the introduction of biologic agents but little is…
Abstract Number: 2488 • 2015 ACR/ARHP Annual Meeting
Impact of Protocolized Tight Control and Biological Dose Optimization in Daily Clinical Practice: Results of a Pilot Implementation Study
Nienke Lesuis¹, George Bruyn², Paul Baudoin², Lieke Nieboer³ and Alfons den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, MC Zuiderzee, Lelystad, Netherlands, ³rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: It is possible to optimize and reduce the individual dose of biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) in patients with rheumatic diseases, in combination…
Abstract Number: 433 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Machaon Bonafede¹, Jeffrey R. Curtis², Donna McMorrow¹, Chieh-I Chen³ and George J. Joseph⁴, ¹Truven Health Analytics, Cambridge, MA, ²Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ
Background/Purpose: A majority of RA patients who switch from a tumor necrosis factor inhibitor (TNFi) to another biologic disease-modifying anti-rheumatic drug (DMARD) are TNFi cyclers…
Abstract Number: 1204 • 2015 ACR/ARHP Annual Meeting
Measuring the Effectiveness of Patient Education of Patients Receiving Injectable Biologic Medications
Victoria Ruffing¹, Ana-Maria Orbai² and Clifton O. Bingham III³, ¹Medicine JHAAC, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Injectable biologic medications have become part of the routine treatment rheumatoid arthritis (RA), and other inflammatory arthritides. These medications are associated with potentially serious…
Abstract Number: 2521 • 2015 ACR/ARHP Annual Meeting
Pregnancies in Patients with Long-Standing Rheumatoid Arthritis and Biologic DMARD Treatment: Course of Disease during Pregnancy and Pregnancy Outcomes
Anja Strangfeld¹, Dagmar Pattloch¹, Madlen Spilka², Bernhard Manger³, Brigitte Krummel-Lorenz⁴, Annett Gräßler⁵, Joachim Listing⁶ and Angela Zink^1,7, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, Erlangen, Germany, ⁴Rheumatologist, Frankfurt, Germany, ⁵Rheumatologist, Pirna, Germany, ⁶Epidemiologiy, German Rheumatism Research Center, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany
Background/Purpose: The assumption of spontaneous remission among pregnant women with rheumatoid arthritis (RA) is common. Nevertheless, prospectively collected data describing the course of disease activity…
Abstract Number: 450 • 2015 ACR/ARHP Annual Meeting
Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: It is well accepted that patients studied in pharmaceutically sponsored clinical trials do not always represent the types of patients seen in clinical practice. …
Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
Abstract Number: 2642 • 2015 ACR/ARHP Annual Meeting
Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy
Norman B. Gaylis¹, Joanne Sagliani¹, Danny Tuccitto², Shawn Black³, Kehzen Tang⁴, Raphael Dehoratius^3,5 and Dennis Parenti³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²AARDS Research, Inc, Aventura, FL, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Patient-reported outcomes (PRO) are used to assess patient related benefit in clinical trials. Rheumatoid arthritis (RA) patients are equally receptive to intravenous (IV) or…
Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Janet E. Pope¹, Emmanouil Rampakakis² and John S. Sampalis³, ¹University of Western Ontario, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Clinical Research, JSS Medical Research, Westmount, QC, Canada
Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…
Abstract Number: 1408 • 2015 ACR/ARHP Annual Meeting
Cogan Syndrome: Differential Response to Biologic Agents and Role of PET-CT in the Increased Diagnosis of Aortitis
Bahtiyar Toz¹, Burak Erer², Sevil Kamali², Ilknur Tugal-tutkun³, Lale Ocal² and Ahmet Gul⁴, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁴Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine,, Istanbul, Turkey
Background/Purpose: Cogan syndrome (CS) is a rare inflammatory disorder typically characterized by interstitial keratitis and audiovestibular symptoms, and patients may also develop other inflammatory ocular…
Abstract Number: 2739 • 2015 ACR/ARHP Annual Meeting
Survival of Etanercept (ETN) Responders after Methotrexate (MTX) Failure When ETN Is Initiated As Mono or Combination Therapy or after MTX Withdrawal from ETN/MTX Combination in Long Standing Rheumatoid Arthritis (RA). a Single Center Retrospective Study
Edward C. Keystone¹, Abdulaziz ALKhalaf^2,3, Sabri ALSaeedi^4,5, Mosaab Makkawy^4,6, Deborah Weber⁷ and Daming Lin⁸, ¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology Division, Medicine Department, UNIVERSITY OF TORONTO/Mount Sinai Hospital, Toronto, ON, Canada, ³Rheumatology Division, Medicine Department, King Saud University, Riyadh, Saudi Arabia, ⁴Rheumatology Division, Medicine Department, UNIVERSITY OF TORONTO/ Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Division, Medicine Department, King Fahd Hospital, Jeddah, Saudi Arabia, ⁶Rheumatology Division, Medicine Department, Prince Mohammad Bin Abdulaziz Hospital, Riyadh, Saudi Arabia, ⁷Advanced Therapeutics, Mt Sinai Hosp 2nd Floor 02-205, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: The long term sustainability of ETN as monotherapy (mono) or in combination (combo) with methotrexate (MTX) is uncertain in patients with longstanding RA responding…
Abstract Number: 486 • 2015 ACR/ARHP Annual Meeting
Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort
Dennis Parenti¹, Shelly Kafka¹, George W. Reed², Jeffrey D. Greenberg^2,3 and Raphael DeHoratius^1,4, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Corrona, LLC, Southborough, MA, ³NYU School of Medicine, New York, NY, ⁴Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The objective of this analysis was to examine persistence with intravenous (IV) and subcutaneous (SC) anti-TNF therapies among rheumatoid arthritis (RA) patients (pts) within…
Abstract Number: 1653 • 2015 ACR/ARHP Annual Meeting
Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis
Leslie Harrold^1,2, J. Lynn Palmer³, Jeffrey R. Curtis⁴, Jeffrey D. Greenberg^2,5 and Joel M. Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Corrona Research Foundation, Albany, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵NYU School of Medicine, New York, NY, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: There is a growing emphasis on treating patients to a target level of low disease activity (LDA) or remission to order to improve outcomes…
Abstract Number: 2756 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed^2,4, Chitra Karki², YouFu Li⁴, Joel M. Kremer⁵, Tmirah Haselkorn⁶ and Jeffrey D. Greenberg^2,7, ¹Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Albany Medical College, Albany, NY, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY
Background/Purpose: The objective of this real-world analysis was to examine the impact of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) on patient-reported outcomes (PROs) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].